Moderna and Merck just dropped positive Phase 3 results for their personalized mRNA cancer vaccine + Keytruda in high-risk melanoma. Stock went absolute nuclear. Deserved. But here’s the interesting part for the autists who like asymmetric bets: There’s a tiny Canadian company called Sona Nanotech (CSE: SONA / OTC: SNANF) that’s attacking a similar problem from a completely different angle. Moderna’s approach: Sequence the patient’s tumor → make a custom mRNA vaccine with selected neoantigens →
CryptoAlerta — análise de criptomoedas e mercado em tempo real